Open AccessCirculating Levels of Sclerostin Are Increased in Patients with Type 2 Diabetes Mellitus
Author(s) -
Antonia García-Martín,
Pedro Rozas-Moreno,
Rebeca Reyes-García,
Sonia Morales-Santana,
Beatriz García-Fontana,
José A. GarcíaSalcedo,
Manuel MuñozTorres
Publication year - 2012
Publication title -
the journal of clinical endocrinology and metabolism/journal of clinical endocrinology and metabolism
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.206
H-Index - 353
eISSN - 1945-7197
pISSN - 0021-972X
DOI - 10.1210/jc.2011-2186
Subject(s) - sclerostin , medicine , endocrinology , bone remodeling , type 2 diabetes mellitus , glycated hemoglobin , bone mineral , femoral neck , diabetes mellitus , osteoporosis , type 2 diabetes , chemistry , biochemistry , wnt signaling pathway , gene
Diabetes mellitus is a risk factor for osteoporotic fractures. Sclerostin is an inhibitor of bone formation. However, there are no data about sclerostin levels in type 2 diabetes mellitus (T2DM).